There is increasing evidence in the literature that androgen deprivation therapy (ADT) is overused among practising urologists in the setting of localized, and even locally advanced, prostate cancer (PCa). Morgia et al. report a misuse of ADT prescriptions among Italian urologists in roughly a quarter of cases, mainly in the setting of low-risk/localized disease where ADT may harm patients without proven benefit with regard to disease-specific outcomes. Such clinical practice behaviours are even more unjustifiable given the high level of evidence upon which the current European Association of Urology (EAU) guidelines recommendations on ADT use are based.
Briganti, A., MacLennan, S., Marconi, L., Plass, K., N'Dow, J., & EAU Guidelines Office ‘IMAGINE’ project (2016). European Association of Urology (EAU) guidelines: do we care? Reflections from the EAU Impact Assessment of Guidelines Implementation and Education group. BJU International, 117(6), 850-851. https://doi.org/10.1111/bju.13383